# Pathological and Functional Brain Amyloids: A New Concept Explaining the Differences

**Authors:** Alexey P. Galkin, Vladimir A. Mitkevich, Alexander A. Makarov, Anna A. Valina, Evgeniy I. Sysoev

PMC · DOI: 10.3390/ijms262110459 · 2025-10-28

## TL;DR

The paper explains how some brain amyloids are harmful while others are not, based on their interactions with specific targets.

## Contribution

The paper introduces the concept of 'available targets' to explain amyloid toxicity, contrasting with previous assumptions about amino acid composition.

## Key findings

- Pathological and functional amyloids do not differ in amino acid composition.
- Amyloid toxicity is determined by interactions with specific targets like PrPC or mitochondrial membranes.
- Functional amyloids avoid harmful targets due to localized translation or interactions with physiological partners.

## Abstract

In recent years, amyloid proteins that perform vital functions in the brain have been characterized. The question of why some amyloids are neurotoxic while others are harmless remains open. Here, we provide a brief overview of pathological and functional brain amyloids and present a comparative analysis of their amino acid sequences based on the percentage of hydrophobic and charged residues, as well as their enrichment in glutamine, asparagine, serine, and glycine. We demonstrate that pathological and functional brain amyloid proteins, along with their amyloidogenic fragments, do not differ in amino acid composition, contrary to previous assumptions. The ability of an amyloid to cause toxicity can instead be explained by the concept of “available targets”. Evidence from studies of pathological amyloids demonstrate that their toxicity is determined not only by a loss of function but also by aberrant interactions with specific targets, such as PrPC or mitochondrial membranes. Binding to these targets triggers pathological cascades that ultimately lead to cell death. In contrast, such targets are inaccessible to functional amyloids, either because of localized translation and protein sequestration within specialized cellular structures, or because their interactions with physiological partners prevent binding to dangerous targets.

## Linked entities

- **Proteins:** PRNP (prion protein (Kanno blood group))

## Full-text entities

- **Genes:** PRNP (prion protein (Kanno blood group)) [NCBI Gene 5621] {aka ASCR, AltPrP, CD230, CJD, GSS, KURU}
- **Diseases:** Brain Amyloids (MESH:D001927), neurotoxic (MESH:D020258), toxicity (MESH:D064420), amyloid (MESH:C000718787)
- **Chemicals:** serine (MESH:D012694), glutamine (MESH:D005973), glycine (MESH:D005998), asparagine (MESH:D001216)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12609487/full.md

---
Source: https://tomesphere.com/paper/PMC12609487